EPRX
Eupraxia Pharmaceuticals Inc.
$6.92
+0.27 (+4.06%)
At close · Jul 8
Market Cap
$452.06M
Shares
65,326,947
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.92
Open$6.59
Day$6.37–6.94
52W$4.88–9.32
Avg vol 30d355K
Short int4.6M · 7.0% float · 16.3d
Short vol74%
DataApr 2024–Jul 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+2%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
−17%
trailing
YTD return
−8%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+54% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.04% of float · ▲ +12.7% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
54 holders — near 2-yr high, broad support
Squeeze score
70
high risk · 0–100
Fundamentals
EPS growth
−36%
Y/Y
Balance sheet
$80.6M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+2%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow
Accumulating
+54% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.04% of float · ▲ +12.7% MoM · 16.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
54 holders — near 2-yr high, broad support
Price context
position in its 52-week range
52-wk low $5
Now $7 · 46%
52-wk high $9
vs 200-day avg -1%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EPRX
this stock
Eupraxia Pharmaceuticals Inc.
|
$452.06M | -8.3% | — | — | 7.0% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EPRX | +4.7% | +15.5% | -16.7% | +4.7% | -8.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +4.9% | +14.7% | -24.2% | +4.9% | -17.7% |